Gemtuzumab and haemoglobin decreased Patient Reports February 13, 2012

Gemtuzumab Side Effects Report #5023836-5
Gemtuzumab side effect was reported by a Health Professional from FRANCE on May 30, 2006. Male patient, 38 years of age, was diagnosed with myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: blast cells present, disease progression, haemoglobin decreased, interstitial lung disease, leukocytosis, leukostasis, malignant neoplasm progression, myeloid leukaemia. Gemtuzumab dosage: 5 MG 1X PER 1 DAY INTRAVENOUS; SEE IMAGE. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN, GEMTUZUMAB OZOGAMICIN, HYDREA, FLUCONAZOLE, FANSIDAR, ZOVIRAX, BACTRIM. Patient was hospitalized. Patient died.

Gemtuzumab Side Effects Report #5061707-9
Gemtuzumab side effect was reported by a Consumer or non-health professional from POLAND on July 11, 2006. Female patient, 23 years of age, was diagnosed with myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: aspartate aminotransferase decreased, atelectasis, condition aggravated, enterococcal infection, fibrin d dimer increased, gamma-glutamyltransferase increased, haemoglobin decreased, hepatomegaly, hyperbilirubinaemia. Gemtuzumab dosage: 3 MG/M^2 1X PER 1 DAY INTRAVENOUS. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN, CANCIDAS, FENTANYL, AMIKIN. Patient died.

Gemtuzumab Side Effects Report #5028040-2
Gemtuzumab side effect was reported by a Consumer or non-health professional from POLAND on May 30, 2006. Female patient, 23 years of age, was diagnosed with myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: condition aggravated, haemoglobin decreased, hepatomegaly, hyperbilirubinaemia, pneumonia , prothrombin level increased, pseudomonal sepsis, white blood cell count decreased. Gemtuzumab dosage: unknown. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN, CANCIDAS, FENTANYL, AMIKIN. Patient recovered.

Gemtuzumab Side Effects Report #5035412-9
Gemtuzumab side effect was reported by a Consumer or non-health professional from POLAND on June 09, 2006. Female patient, 23 years of age, was diagnosed with myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: atelectasis, condition aggravated, fibrin d dimer increased, haemoglobin decreased, hepatomegaly, hyperbilirubinaemia, platelet count decreased, pneumonia , pseudomonal sepsis. Gemtuzumab dosage: unknown. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN, CANCIDAS, FENTANYL TRANSDERMAL SYSTEM, AMIKIN. Patient recovered.


Gemtuzumab Side Effects Report #4677726-8
Gemtuzumab side effect was reported by a Consumer or non-health professional from on May 18, 2005. Male patient, 41 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: balanoposthitis, culture positive, haemoglobin decreased, platelet count decreased, staphylococcal sepsis, urinary tract infection pseudomonal, white blood cell count decreased. Gemtuzumab dosage: 10.2 MG 1X PER 1 DAY. Patient was hospitalized. Patient recovered.

Gemtuzumab Side Effects Report #4680268-7
Gemtuzumab side effect was reported by a Consumer or non-health professional from on May 19, 2005. Male patient, 41 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: balanoposthitis, haemoglobin decreased, neutropenia, platelet count decreased, pseudomonas infection, staphylococcal sepsis. Gemtuzumab dosage: 10.2 MG 1X PER 1 DAY. During the same period patient was treated with FEXOFENADINE, ESOMEPRAZOLE, MAGALDRATE, DEXAMETHASONE, CHLORPHENAMINE, ONDANSETRON, ELECTROLYTE SOLUTIONS, BICARBONATE IN PLASTIC CONTAINER. Patient was hospitalized. Patient recovered.

Gemtuzumab Side Effects Report #5020474-5
Gemtuzumab side effect was reported by a Consumer or non-health professional from BELGIUM on May 24, 2006. Female patient, 27 years of age, was diagnosed with acute myeloid leukaemia recurrent and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: blast cells present, blood urea increased, haematocrit decreased, haemoglobin decreased, monocyte count increased, neutrophil count decreased, platelet count decreased, red blood cell count decreased, venoocclusive liver disease. Gemtuzumab dosage: 14, 9 MG INTRAVENOUS. During the same period patient was treated with OMEPRAZOLE, FLUCONAZOLE, ACYCLOVIR, TARIVID, MAGNESIUM, FOLIC ACID, LYNESTRENOL, FRAXIPARINE. Patient died.

Gemtuzumab Side Effects Report #4927935-5
Gemtuzumab side effect was reported by a Consumer or non-health professional from DENMARK on Feb 10, 2006. Male patient was diagnosed with acute myeloid leukaemia recurrent and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: blood creatine phosphokinase increased, blood lactate dehydrogenase increased, haemoglobin decreased, haemolysis, infection , neutrophil count increased, thrombocytopenia. Gemtuzumab dosage: 3.8 MG 1X PER 1 DASY, INTRAVENOUS. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN. Patient recovered.

Gemtuzumab Side Effects Report #4911220-1
Gemtuzumab side effect was reported by a Consumer or non-health professional from SPAIN on June 28, 2001. Male patient, 65 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: blood potassium decreased, catheter related infection, haemoglobin decreased, neutropenia, platelet count decreased, post procedural complication, staphylococcal infection . Gemtuzumab dosage: 6 MG/M^2 1X PER 1 DOS INTRAVENOUS. During the same period patient was treated with CYTARABINE, DAUNORUBICIN. Patient was hospitalized. Patient recovered.


Gemtuzumab Side Effects Report #4906851-9
Gemtuzumab side effect was reported by a Consumer or non-health professional from ITALY on Jan 27, 2006. Female patient, 63 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: haemoglobin decreased, lung infection, platelet count decreased, red blood cell count increased, respiratory failure, staphylococcal infection . Gemtuzumab dosage: unknown. Patient died.

Gemtuzumab Side Effects Report #5028048-7
Gemtuzumab side effect was reported by a Consumer or non-health professional from UNITED KINGDOM on Dec 29, 2005. Female patient, 63 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood disorder, diarrhoea, haemoglobin decreased, lethargy, loss of consciousness, lower respiratory tract infection, neutrophil count decreased. Gemtuzumab dosage: unknown. Patient was hospitalized. Patient died.

Gemtuzumab Side Effects Report #4845443-7
Gemtuzumab side effect was reported by a Consumer or non-health professional from AUSTRALIA on Nov 21, 2005. Male patient, 57 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, anxiety , blood alkaline phosphatase increased, blood lactate dehydrogenase increased, bone marrow failure, gamma-glutamyltransferase increased, haematocrit decreased, haemoglobin decreased, lymphocyte count decreased. Gemtuzumab dosage: unknown. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN, CYTARABINE, PHENERGAN, HYDROCORTISONE, PREDNISONE, ATENOLOL, FLUCONAZOLE, FOLIC ACID. Patient was hospitalized. Patient died.

Gemtuzumab Side Effects Report #4867026-5
Gemtuzumab side effect was reported by a Consumer or non-health professional from FRANCE on Mar 10, 2002. Male patient, 57 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: aplasia, blast cell count increased, chills, haemoglobin decreased, leukopenia, neutrophil count decreased, neutrophil percentage decreased, pyrexia, thrombocytopenia. Gemtuzumab dosage: 9 MG/M2 INTRAVENOUS. Patient was hospitalized. Patient recovered.

Gemtuzumab Side Effects Report #4914117-6
Gemtuzumab side effect was reported by a Consumer or non-health professional from UNITED KINGDOM on Jan 09, 2002. Female patient, 33 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: haemoglobin decreased, neutropenia, platelet count decreased, pyrexia, tooth abscess. Gemtuzumab dosage: 9 MG/^2 1X PER 1 DOS. Patient was hospitalized. Patient recovered.


Gemtuzumab Side Effects Report #4802362-X
Gemtuzumab side effect was reported by a Consumer or non-health professional from BELGIUM on Sept 30, 2005. Female patient, 69 years of age, was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: atrial fibrillation , blood fibrinogen increased, febrile neutropenia, fibrin d dimer increased, haematocrit decreased, haemoglobin decreased, hypoxia, lymphocyte count increased, neutrophil count decreased. Gemtuzumab dosage: 14 MG. During the same period patient was treated with ALIZAPRIDE, BUMETANIDE, PETHIDINE HYDROCHLORIDE. Patient was hospitalized. Patient died.

Gemtuzumab Side Effects Report #4805266-1
Gemtuzumab side effect was reported by a Consumer or non-health professional from BELGIUM on Oct 12, 2005. Female patient, 69 years of age, was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: atrial fibrillation , blood fibrinogen increased, c-reactive protein increased, febrile neutropenia, fibrin d dimer increased, haematocrit decreased, haemoglobin decreased, hypoxia, lymphocyte count increased. Gemtuzumab dosage: 14 MG. During the same period patient was treated with ALIZAPRIDE, BUMETANIDE, PETHIDINE HYDROCHLORIDE. Patient was hospitalized. Patient died.

Gemtuzumab Side Effects Report #5055223-8
Gemtuzumab side effect was reported by a Consumer or non-health professional from ITALY on July 03, 2006. Female patient, 63 years of age, was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: blood ph increased, haemoglobin decreased, lung infection, platelet count decreased, red blood cell count decreased, respiratory failure, staphylococcal infection . Gemtuzumab dosage: 10 MG. During the same period patient was treated with CYTARABINE, ETOPOSIDE, NOVANTRONE, LEVOFLOXACIN. Patient died.